Adaptive Biotechnologies Corporation (ADPT)
| Market Cap | 4.74B |
| Revenue (ttm) | 133.43M |
| Net Income (ttm) | -171.23M |
| Shares Out | 140.36M |
| EPS (ttm) | -1.24 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 253,231 |
| Open | 33.80 |
| Previous Close | 33.92 |
| Day's Range | 32.97 - 34.17 |
| 52-Week Range | 29.74 - 71.25 |
| Beta | 0.30 |
| Analysts | Buy |
| Price Target | 56.67 (+68.5%) |
| Est. Earnings Date | Nov 3, 2021 |
About ADPT
Adaptive Biotechnologies Corporation, a commercial-stage company, develops an immune medicine platform for the diagnosis and treatment of various diseases. The company offers immunoSEQ research service and kit that is used to answer translational research questions, as well as to discover new prognostic and diagnostic signals; and T-Detect COVID for the confirmation of past COVID-19 infection. It also provides clonoSEQ diagnostic tests, which include immunosequencing services for use in the detection and monitoring of minimal residual disease i...
Financial Performance
In 2020, ADPT's revenue was $98.38 million, an increase of 15.65% compared to the previous year's $85.07 million. Losses were -$146.23 million, 113.1% more than in 2019.
Financial StatementsAnalyst Forecast
According to 8 analysts, the average rating for ADPT stock is "Buy." The 12-month stock price forecast is 56.67, which is an increase of 68.46% from the latest price.
News
Adaptive Biotechnologies to Report Third Quarter Financial Results on November 3, 2021
SEATTLE, Oct. 06, 2021 (GLOBE NEWSWIRE) -- Adaptive Biotechnologies Corporation (Nasdaq: ADPT), a commercial stage biotechnology company that aims to translate the genetics of the adaptive immune system...
Adaptive Biotechnologies Presents New Data During IDWeek Demonstrating the Capability of Its Immune Medicine Platform...
Real-world data show T-Detect™ COVID can detect prior SARS-CoV-2 infection nearly 12 months after initial diagnosis in some patients
Adaptive Biotechnologies Launches Enhanced clonoSEQ® Assay Reports for Patients with Chronic Lymphocytic Leukemia, No...
Combined ID-IGHV report at time of diagnosis conveniently provides additional prognostic information while also enabling future MRD monitoring in patients Combined ID-IGHV report at time of diagnosis co...
Adaptive Biotechnologies Announces Grand Opening of State-of-the-Art Headquarters and Expands Footprint in Seattle
New Partnership with Youth Organization STEM Paths Innovation Network (SPIN) Seeds Next Generation of Local Biotech Talent New Partnership with Youth Organization STEM Paths Innovation Network (SPIN) Se...
Adaptive Biotechnologies to Present New SARS-CoV-2 Data from its Immune Medicine Platform During IDWeek 2021
Research demonstrates the ability of Adaptive's immune medicine platform to distinguish natural infection from vaccine response and the ability to detect prior infection nearly 12 months after initial d...
Adaptive Biotechnologies to Present at the Morgan Stanley Global Healthcare Conference
SEATTLE, Sept. 07, 2021 (GLOBE NEWSWIRE) -- Adaptive Biotechnologies Corporation (Nasdaq: ADPT) a commercial stage biotechnology company that aims to translate the genetics of the adaptive immune system...
3 Life Science Stocks Cathy Wood's Buying Hand Over Fist Right Now
ARK Invest made multiple purchases of these stocks last week.
Curebase, Adaptive Biotechnologies Announce Collaboration to Expand Clinical Study Access
SAN FRANCISCO and SEATTLE, Aug. 10, 2021 /PRNewswire/ -- Curebase, a company committed to democratizing access to clinical studies, and Adaptive Biotechnologies Corp. (Nasdaq: ADPT), a biotechnology com...
Adaptive Biotechnologies (ADPT) Reports Q2 Loss, Tops Revenue Estimates
Adaptive Biotechnologies (ADPT) delivered earnings and revenue surprises of 18.60% and 20.16%, respectively, for the quarter ended June 2021. Do the numbers hold clues to what lies ahead for the stock?
Adaptive Biotechnologies Appoints Nitin Sood as Chief Commercial Officer
Diagnostics industry expert to lead commercialization of marketed products and drive global commercial expansion Diagnostics industry expert to lead commercialization of marketed products and drive glob...
Earnings Preview: Adaptive Biotechnologies (ADPT) Q2 Earnings Expected to Decline
Adaptive Biotechnologies (ADPT) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Adaptive Biotechnologies to Report Second Quarter Financial Results on August 4, 2021
SEATTLE, July 12, 2021 (GLOBE NEWSWIRE) -- Adaptive Biotechnologies Corporation (Nasdaq: ADPT) a commercial stage biotechnology company that aims to translate the genetics of the adaptive immune system...
This Explosive Biotech Is Taking On a Huge New Market
Dominant in its core reproductive health market, niche medical diagnostics company Natera now has its sights on the crowded oncology diagnostics space.
Adaptive Biotechnologies (ADPT) Upgraded to Buy: Here's Why
Adaptive Biotechnologies (ADPT) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
New Study Published in Nature Provides Further Evidence that COVID-19 Vaccine Induced T-Cell Response Targets Known S...
Adaptive's immunoSEQ T-MAP COVID provides potential explanation for preservation of Johnson & Johnson vaccine (Ad26.COV2.S) response to variants even when neutralizing antibodies are diminished Adaptive...
Adaptive Biotechnologies Included in More than 20 Abstracts at ASCO and EHA 2021 Highlighting Expanding Use Cases for...
Studies demonstrate value of MRD in novel treatment settings including CAR T cell therapy and in a growing range of patient types, including Non-Hodgkin's Lymphoma Studies demonstrate value of MRD in no...
Adaptive Biotechnologies to Participate in Upcoming June 2021 Investor Conferences
SEATTLE, May 20, 2021 (GLOBE NEWSWIRE) -- Adaptive Biotechnologies Corporation (Nasdaq: ADPT) a commercial stage biotechnology company that aims to translate the genetics of the adaptive immune system i...
Adaptive Biotechnologies (ADPT) Reports Q1 Loss, Tops Revenue Estimates
Adaptive Biotechnologies (ADPT) delivered earnings and revenue surprises of 29.27% and 34.73%, respectively, for the quarter ended March 2021. Do the numbers hold clues to what lies ahead for the stock?
Adaptive Biotechnologies Reports First Quarter 2021 Financial Results
SEATTLE, May 05, 2021 (GLOBE NEWSWIRE) -- Adaptive Biotechnologies Corporation (“Adaptive Biotechnologies”) (Nasdaq: ADPT), a commercial stage biotechnology company that aims to translate the genetics o...
Earnings Outlook for Adaptive Biotechnologies
Adaptive Biotechnologies (NASDAQ:ADPT) announces its next round of earnings this Wednesday, May 05. Here is Benzinga's everything-that-matters guide for this Wednesday's Q1 earnings announcement.
Earnings Preview: Adaptive Biotechnologies (ADPT) Q1 Earnings Expected to Decline
Adaptive Biotechnologies (ADPT) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Adaptive Biotechnologies to Present at the BofA Securities 2021 Virtual Healthcare Conference
SEATTLE, April 27, 2021 (GLOBE NEWSWIRE) -- Adaptive Biotechnologies Corporation (Nasdaq: ADPT) a commercial stage biotechnology company that aims to translate the genetics of the adaptive immune system...
Andreas Halvorsen Takes Stake in Mudrick Capital Acquisition Following Merger Announcement
Viking Global leader Andreas Holversen disclosed a stake in Mudrick Capital Acquistion Corp. II (NASDAQ:MUDS) earlier this month, seeing yet another value opportunity in special purpose acquisition comp...
GenomeWeb Index Drops 3% for 2nd Consecutive Month
Meridian Bioscience Inc. (NASDAQ:VIVO) edged out GenMark Diagnostics Inc. (NASDAQ:GNMK) as the top gainer in the March GenomeWeb Index with a 25% boost in its share price compared to GenMark's 22.5% inc...